Axonics
Company developing novel implantable neuromodulation.
Launch date
Employees
Market cap
€3.2b
Enterprise valuation
€2.9b (Public information from Sep 2024)
Share price
$69.25 AXNX
Irvine California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 112m | 180m | 274m | 366m | 448m | 534m | 640m |
| % growth | 707 % | 62 % | 52 % | 34 % | 22 % | 19 % | 20 % |
| EBITDA | (53.0m) | (60.1m) | (27.9m) | 29.1m | 14.0m | 48.7m | 99.1m |
| % EBITDA margin | (48 %) | (33 %) | (10 %) | 8 % | 3 % | 9 % | 15 % |
| Profit | (54.9m) | (80.1m) | (59.7m) | (6.1m) | 10.2m | 40.7m | 68.5m |
| % profit margin | (49 %) | (44 %) | (22 %) | (2 %) | 2 % | 8 % | 11 % |
| EV / revenue | 15.8x | 13.2x | 10.0x | 7.7x | 7.2x | 5.9x | 4.8x |
| EV / EBITDA | -33.3x | -39.5x | -98.3x | 96.4x | 229.0x | 65.0x | 31.1x |
| R&D budget | 29.2m | 37.3m | 34.4m | 34.9m | - | - | - |
| R&D % of revenue | 26 % | 21 % | 13 % | 10 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$32.6m | Series A | ||
$17.3m | Series B | ||
$38.5m | Series B | ||
| N/A | $14.5m | Series C | |
$20.0m | Debt | ||
$20.1m | Series C | ||
| N/A | $120m Valuation: $400m 3125.0x EV/LTM Revenues -23.1x EV/LTM EBITDA | IPO | |
* | $10.7m | Post IPO Equity | |
* | $3.7b Valuation: $3.7b 10.1x EV/LTM Revenues 127.0x EV/LTM EBITDA | Acquisition | |
| Total Funding | €112m | ||
